Eli Lilly and Co (LLY)

Industry Drug Manufacturers - General

This stock can be held in an Investment ISA and an Investment Account

Sell

$1,011.50

Buy

$1,012.00

arrow-down$-13.70 (-1.34%)

Prices updated at 21 Feb 2026, 00:59 EST

Prices minimum 15 mins delay

Prices in USD

Eli Lilly and Co is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. It discovers, develops, manufactures, and sells human pharmaceutical products and animal health products.

S&P 500

0.69%

NYSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Drug Manufacturers - General

Chairman

Mr. David A. Ricks

CEO

Mr. David A. Ricks

Most recent earnings

31 Dec 2025

Fiscal year end

31 Dec 2025

Employees

50,000

Head office

Lilly Corporate Center

Indianapolis

United States

46285

+1 317 276-2000

jfletcher@lilly.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Ms. Gabrielle Sulzberger, J.D.,M.B.A. Independent Director	0.12m
Mr. Jon Erik Fyrwald Independent Director	0.12m
Mr. Juan R. Luciano Lead Independent Director	0.18m
Mr. Jon R. Moeller Independent Director	0.01m
Dr. Mary Lynne Hedley,PhD Independent Director	0.12m
Mr. Ralph Alvarez Independent Director	0.14m
Dr. Katherine Baicker, PhD Independent Director	0.14m
Mr. David A. Ricks Chairman of the Board, President and Chief Executive Officer	1.69m
Dr. William G. Kaelin, Jr,M.D. Independent Director	0.14m
Mr. Donald A. Zakrowski Senior Vice President, Finance and Chief Accounting Officer	-
Mr. Jamere Jackson Independent Director	0.15m
Mr. Jacob S. Van Naarden Executive Vice President, President, Lilly Oncology and Head of Corporate Business Development	0.89m
Ms. Kimberly H. Johnson Independent Director	0.12m
Ms. Anat Hakim Executive Vice President, General Counsel and Secretary	1.00m
Dr. Carolyn R. Bertozzi, PhD Independent Director	-
Dr. Carole Ho, M.D. Executive Vice President and President, Lilly Neuroscience	-
Dr. Daniel M. Skovronsky, M.D.,PhD Executive Vice President, Chief Scientific and Product Officer and President, Lilly Research Laboratories	1.43m
Mr. Lucas Montarce Executive Vice President and Chief Financial Officer	0.66m
Mr. Patrik Jonsson Executive Vice President and President, Lilly International	-
Mr. Ilya Yuffa Executive Vice President and President, Lilly USA and Global Customer Capabilities	-
Mr. Edgardo Hernandez Executive Vice President and President, Manufacturing Operations	-
Mr. Diogo Rau Executive Vice President, Chief Information Officer and Chief Digital Officer	-
Mr. Eric Dozier Executive Vice President and Chief People Officer	-
Ms. Melissa Seymour Executive Vice President, Global Quality	-
Dr. Kenneth L. Custer, PhD Executive Vice President and President, Lilly Cardiometabolic Health	-
Ms. Adrienne S Brown Executive Vice President and President, Lilly Immunology	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Lilly Endowment Inc	92,190,516
Vanguard Group Inc	81,965,974
BlackRock Inc	65,809,763
PNC Financial Services Group Inc	51,364,189
Capital Research and Management Company	48,015,459

Director dealings

Date chevron-l-regular chevron-r-regular	Action
15 Dec 2025	-
15 Dec 2025	-
15 Dec 2025	-
15 Dec 2025	-
15 Dec 2025	-
17 Nov 2025	-
17 Nov 2025	-
17 Nov 2025	-
17 Nov 2025	-
17 Nov 2025	-
17 Nov 2025	-
17 Nov 2025	-
17 Nov 2025	-
17 Nov 2025	-
17 Nov 2025	-
17 Nov 2025	-
17 Nov 2025	-
17 Nov 2025	-
17 Nov 2025	-
17 Nov 2025	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.